---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006511"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T15:20:40.089458+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncocyte appoints Joshua Riggs as permanent CEO, President, and Board member

## Summary
- Joshua Riggs appointed CEO effective Feb 24, 2023; also named President and joined Board on Feb 28.
- Riggs served as interim CEO since Dec 2022, leading restructuring and cost reduction initiatives.
- Board unanimously supports Riggs' appointment; Chair Andy Arno cites rapid spend reduction and strategic refocus.
- Riggs previously held roles as General Manager, Transplant and Senior Director of Business Development at Oncocyte.
- Company continues focus on precision diagnostics: DetermaIO, VitaGraft, and pipeline test DetermaCNI.

## SEC filing metadata
- accession: 0001493152-23-006511
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006511
- JSON: https://secwatch.observer/filing/0001493152-23-006511.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006511.txt

## Key facts
- Executive change
  Joshua Riggs was appointed as Chief Executive Officer at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Effective February 24, 2023, the Board of Directors of Oncocyte Corporation (“Oncocyte” or the “Company”) appointed Joshua Riggs as Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm
- Executive change
  Joshua Riggs was appointed as Director at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: Director
  source text: Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm
- Executive change
  Joshua Riggs was appointed as President at Insight Molecular Diagnostics Inc..
  - Action: appointed
  - Role: President
  source text: Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.